Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast

Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on May 3rd, 2022, at 4:30 pm ET to discuss its financial results for the first quarter of 2022. The call can be accessed via a webcast that will be available on Infinity's website for 30 days post-event. Infinity is focused on developing eganelisib, an oral immuno-oncology therapeutic, with several pivotal trials expected to initiate, including the MARIO-4 trial in mTNBC and MARIO-3 for advanced cancer.

Positive

• Expected initiation of MARIO-4 trial by end of 2022.
• Ongoing development of eganelisib in various cancer indications.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022.

Conference Call & Webcast Details
Date:		Tuesday, May 3rd
Time:		4:30 pm Eastern Time
Webcast:		https://edge.media-server.com/mmc/p/prmegw6b
Toll Free:		(877) 316-5293
International:		(631) 291-4526
ID Number:		6618485

A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at https://www.infi.com/ and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in frontline TNBC and in combination with Tecentriq and Avastin^® in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® (nivolumab) in I/O naïve urothelial cancer. MARIO-P is a platform clinical program to evaluate eganelisib across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC.
Opdivo^® is a registered trademark of Bristol Myers Squibb.
Avastin^® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005162/en/

Irina Koffler

LifeSci Advisors, LLC

646-970-4681

ikoffler@lifesciadvisors.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

When will Infinity Pharmaceuticals report Q1 2022 financial results?

Infinity Pharmaceuticals will report its Q1 2022 financial results on May 3rd, 2022.

What is eganelisib developed by Infinity Pharmaceuticals?

Eganelisib is a first-in-class, oral immuno-oncology therapeutic targeting macrophage reprogramming.

How can I access Infinity Pharmaceuticals' conference call?

The conference call can be accessed via a webcast on Infinity's website at 4:30 pm ET on May 3rd.

What trials is Infinity Pharmaceuticals conducting for eganelisib?

Infinity is conducting several trials, including MARIO-4 for mTNBC and MARIO-3 for combination therapies in advanced cancer.